Health and Healthcare

Alexion Pharmaceuticals, Inc. : ALXN

All ALXN Articles

307 Articles

Chris Lange | Sep 11, 2014 at 9:20 AM EDT

Short Sellers Remain Vigilant Against Biotechs

Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the latest…

Lee Jackson | Sep 8, 2014 at 9:10 AM EDT

SunTrust Robinson Humphrey Starts Coverage on 5 Top Biotech Stocks

SunTrust Robinson Humphrey opens up coverage of the biotech sector with four top biotech stocks to buy and one Neutral-rated…

Chris Lange | Sep 3, 2014 at 11:50 AM EDT

Credit Suisse Positive on Some Biotechs, Very Cautious on Others

Credit Suisse has launched new biotech coverage on Wednesday with two analysts at the firm.

Chris Lange | Aug 27, 2014 at 10:25 AM EDT

Rising Short Interest in Biotech Stocks

Short sellers might be inclined to bet against biotech companies because of their volatile behavior on the charts.

Jon C. Ogg | Jul 20, 2014 at 9:11 AM EDT

Top Biotech Earnings Previews for the Week Ahead

ThinkstockEarnings season is now well under way for the second quarter. So far, things are looking good. The biotech sector…

Lee Jackson | Jul 18, 2014 at 9:15 AM EDT

Analyst Issues Top Biotech Stocks to Buy Ahead of Earnings

ThinkstockFor the third time in less than two weeks, one of the top brokerage firms we cover at 24/7 Wall Street…

Lee Jackson | Jul 9, 2014 at 8:40 AM EDT

UBS Very Bullish on Biotech Stocks Ahead of Second-Quarter Earnings

In a new research report, UBS analysts are very positive on some top biotech stocks before second-quarter earnings numbers hit…

Lee Jackson | Jul 2, 2014 at 9:00 AM EDT

The Path to FDA Approval Could Launch Seven Biotech Stocks Much Higher

A new report from the analysts at Cowen shows that, on average, biotech stocks gained 84% in the 12 months…

Jon C. Ogg | Jun 11, 2014 at 6:50 AM EDT

Short Sellers Remain Vigilant Against Top Biotech Stocks

ThinkstockShort sellers have many reasons to bet against a stock, some of which are hedging or part of a larger…

Trey Thoelcke | Jun 3, 2014 at 8:45 AM EDT

Top Biotech Stocks to Buy According to Portfolio Managers

A new research report from Cowen suggests that biotech investors appear to be looking forward to what they describe as…

Jon C. Ogg | Apr 4, 2014 at 8:20 AM EDT

Stifel Says Strong Earnings Will Reignite Biotech Rally

ThinkstockWhen the biotech sell-off started in late February, the stocks had been market leaders for almost four years. The staggering…

Trey Thoelcke | Mar 24, 2014 at 9:55 AM EDT

Top Biotechnology Stocks On Sale Again

For the second time in less than a month, the biotechnology sector got whacked when once again, chatter coming from…

Jon C. Ogg | Mar 10, 2014 at 10:00 AM EDT

Oppenheimer Top Stocks to Buy as Bull Market Turns Five Years Old

Five years ago, many investors had thrown in the towel. The S&P 500 hit an ominous intraday low of 666…

Trey Thoelcke | Jan 29, 2014 at 8:15 AM EST

UBS Says Buy Top Biotech Stocks in Front of Earnings for Big Upside

Like many firms on Wall Street, the biotechnology team at UBS thinks that most of the top mega-cap and large…

Jon C. Ogg | Jan 14, 2014 at 8:15 AM EST

UBS Has Nine Biotech Buyout and Merger Candidates

The analysts at UBS are not only bullish on the biotechnology sector, they think there is a very distinct possibility…

1 … 16 17 18 19 20 21

Alexion Pharmaceuticals, Inc. : ALXN

All ALXN Articles

Short Sellers Remain Vigilant Against Biotechs

SunTrust Robinson Humphrey Starts Coverage on 5 Top Biotech Stocks

Credit Suisse Positive on Some Biotechs, Very Cautious on Others

Rising Short Interest in Biotech Stocks

Top Biotech Earnings Previews for the Week Ahead

Analyst Issues Top Biotech Stocks to Buy Ahead of Earnings

UBS Very Bullish on Biotech Stocks Ahead of Second-Quarter Earnings

The Path to FDA Approval Could Launch Seven Biotech Stocks Much Higher

Short Sellers Remain Vigilant Against Top Biotech Stocks

Top Biotech Stocks to Buy According to Portfolio Managers

Stifel Says Strong Earnings Will Reignite Biotech Rally

Top Biotechnology Stocks On Sale Again

Oppenheimer Top Stocks to Buy as Bull Market Turns Five Years Old

UBS Says Buy Top Biotech Stocks in Front of Earnings for Big Upside

UBS Has Nine Biotech Buyout and Merger Candidates

Want $1,150 in Passive Income? Invest $10,000 Into These 3 Dividend Aristocrats

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple's $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

Want $1,150 in Passive Income? Invest $10,000 Into These 3 Dividend Aristocrats

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

Alexion Pharmaceuticals, Inc. : ALXN

All ALXN Articles

Short Sellers Remain Vigilant Against Biotechs

SunTrust Robinson Humphrey Starts Coverage on 5 Top Biotech Stocks

Credit Suisse Positive on Some Biotechs, Very Cautious on Others

Rising Short Interest in Biotech Stocks

Top Biotech Earnings Previews for the Week Ahead

Analyst Issues Top Biotech Stocks to Buy Ahead of Earnings

UBS Very Bullish on Biotech Stocks Ahead of Second-Quarter Earnings

The Path to FDA Approval Could Launch Seven Biotech Stocks Much Higher

Short Sellers Remain Vigilant Against Top Biotech Stocks

Top Biotech Stocks to Buy According to Portfolio Managers

Stifel Says Strong Earnings Will Reignite Biotech Rally

Top Biotechnology Stocks On Sale Again

Oppenheimer Top Stocks to Buy as Bull Market Turns Five Years Old

UBS Says Buy Top Biotech Stocks in Front of Earnings for Big Upside

UBS Has Nine Biotech Buyout and Merger Candidates

Want $1,150 in Passive Income? Invest $10,000 Into These 3 Dividend Aristocrats

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

Featured Reads

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple's $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not